|1.||Finer, N: 17 articles (05/2015 - 04/2000)|
|2.||Sharma, Arya M: 13 articles (11/2013 - 09/2002)|
|3.||Sharma, A M: 10 articles (05/2015 - 12/2001)|
|4.||Coutinho, Walmir: 10 articles (11/2013 - 01/2002)|
|5.||Finer, Nick: 9 articles (11/2013 - 08/2003)|
|6.||Scheen, A J: 9 articles (10/2010 - 03/2000)|
|7.||Torp-Pedersen, Christian: 8 articles (11/2013 - 12/2007)|
|8.||James, W P T: 7 articles (05/2015 - 03/2009)|
|9.||Torp-Pedersen, C: 7 articles (05/2015 - 03/2009)|
|10.||Coutinho, W: 6 articles (05/2015 - 03/2009)|
|1.||Weight Loss (Weight Reduction)
01/01/2003 - "The efficacy of sibutramine for inducing initial weight loss and the subsequent maintenance of weight loss is well proven in short- and long-term clinical trials of up to 2 years' duration. "
10/01/2007 - "However, there is some controversy as to whether weight loss is beneficial for health, and large clinical outcome trials such as the Look-AHEAD (Action for Health in Diabetes) trial or the SCOUT (Sibutramine Cardiovascular Outcomes Trial) study are currently ongoing. "
01/01/2007 - "This study confirmed that sibutramine significantly enhances the effect of diet on weight loss, BMI and waist circumference reduction, and showed a significant improvement of QoL."
04/01/2000 - "Mean weight reduction from baseline was statistically significantly greater with sibutramine than with placebo at every measurement and at the end of the study (2.4 vs. 0.1 kg at week 12; p < 0.001; intent-to-treat). "
08/01/2008 - "Sibutramine appears to be safe and effective in producing clinically significant weight loss for up to 1 year. "
09/01/2001 - "The study indicates sibutramine to be an effective and well tolerated agent leading to significant reduction in parameter of obesity in obese type 2 diabetic subjects."
01/01/2004 - "Sibutramine is a cost-effective treatment for obesity when combined with diet and lifestyle advice."
05/26/2000 - "The results suggest that these enantioselective metabolites of sibutramine could be safe and effective treatments for obesity as well as possibly for depression."
01/01/2004 - "Sibutramine is a US Food and Drug Administration- and European Committee for Proprietary Medicinal Products-approved medication with demonstrated efficacy in long-term obesity management. "
10/01/2000 - "An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action."
|3.||Body Weight (Weight, Body)
01/01/2010 - "12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0.05) in all the patients. "
04/17/2007 - "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment. "
06/01/2006 - "After 4 months, however, initial body weight was reduced by 11.4 +/- 1.2% in the sibutramine group compared with only 2.2 +/- 1.3% in controls (p <0.001), demonstrating a significant improvement in postintervention %FMD (8.9 +/- 2.4%, p = 0.01, compared with baseline) in the sibutramine group compared with controls (5.2 +/- 3.6%, p = 0.68, compared with baseline). "
04/01/2005 - "After sibutramine treatment, the decrease in body weight and waist circumference was significantly greater than in the placebo group. "
12/01/2004 - "There was a significant reduction in body weight in both sibutramine-treated diabetic patients (7.1%) and nondiabetic subjects (9.1%), accompanied by a significant reduction in body fat mass. "
05/01/2014 - "This pilot trial suggests that adjunctive treatment with sibutramine may be safe and effective in schizophrenic patients with antipsychotic-induced weight gain."
03/17/2009 - "The present study was therefore designed to assess the effects of acute sibutramine treatment on food intake, the behavioural satiety sequence (BSS) and post-treatment weight gain. "
03/17/2009 - "Single dosing with sibutramine (3.0 mg/kg) also suppressed daily weight gain over the 24-72 h period post-dosing. "
01/01/2008 - "Nine months after stopping the treatment with sibutramine, a partial weight gain was noticed. "
05/01/2002 - "We also detected weight gain in 45.2% of the placebo group compared to 20% in the sibutramine group. "
05/01/2015 - "The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. "
09/01/2014 - "The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. "
06/01/2014 - "Data from the Sibutramine Cardiovascular Outcomes (SCOUT) trial, including almost 10.000 overweight/obese high cardiovascular risk patients, were used. "
03/01/2014 - "A total of 9,687 overweight/obese cardiovascular high-risk patients from the Sibutramine Cardiovascular OUTcomes trial were studied. "
11/01/2013 - "This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized to lifestyle intervention with or without sibutramine for up to 6 years. "
|2.||Serotonin (5 Hydroxytryptamine)
|5.||Anti-Obesity Agents (Antiobesity Drugs)
|1.||Drug Therapy (Chemotherapy)
|3.||Continuous Positive Airway Pressure